Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA

Krchňák, Viktor; Vagner, Josef; Suchánková, Alena; Krcmár, M; Ritterova, L.; Vonka, V.

doi:10.1099/0022-1317-71-11-2719

Cited by 47 publications

(18 citation statements)

References 13 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the number of viral particles produced in these sophisticated systems is prohibitively low to be used in routine antigen prepa- rations. Because of these problems, alternative strategies such as genetically engineered fusion proteins and synthetic peptides are being considered [Jenison et al, 1988;Jochmus-Kudielka et al, 1989;Dillner et al, 1989;Krchnak et al, 1990;Wikstrom et al, 19921. A linear epitope in the carboxyterminal region of the L2 protein of HPV 6111 was found to be preferentially reac-57 [Suchankova et al, 19901.…”

Section: Recurrent Respiratory Papillomatosis (Rrp)mentioning

confidence: 99%

Antibody response to a synthetic peptide derived from the human papillomavirus type 6/11 L2 protein in recurrent respiratory papillomatosis: Correlation between southern blot hybridization, polymerase chain reaction, and serology

Tachezy

Hamšíková

Valvoda

et al. 1994

Journal of Medical Virology

View full text Add to dashboard Cite

Recurrent respiratory papillomatosis (RRP) is the most common benign tumour of the larynx, affecting both children and adults. We present a series of 25 patients, including 10 cases of juvenile multiple, 8 cases of adult solitary, and 7 cases of adult multiple RRP. Biopsy tissue from each patient was screened by Southern blot hybridization and polymerase chain reaction for the presence of human papillomavirus (HPV) DNA. Sera from patients and age- and sex-matched controls were tested for the presence of HPV-specific antibodies using a synthetic peptide derived from the minor capsid protein (L2) of HPV 6/11. By Southern blot hybridization and/or polymerase chain reaction, biopsies from all patients were positive for HPV 6/11 DNA. There was no difference in antibody response between cases and controls. Female cases and controls had significantly higher antibody titers than male subjects. A correlation was observed between the HPV-specific antibody level and the number of surgery-necessitating recurrences.

show abstract

Section: Recurrent Respiratory Papillomatosis (Rrp)mentioning

confidence: 99%

Antibody response to a synthetic peptide derived from the human papillomavirus type 6/11 L2 protein in recurrent respiratory papillomatosis: Correlation between southern blot hybridization, polymerase chain reaction, and serology

Tachezy

Hamšíková

Valvoda

et al. 1994

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…We have investigated the recognition of an HPV E7 epitope, which was also found to be the main immunodominant B cell epitope in humans (65). In addition to its interest for diagnostic applications, the immune response toward this oncoprotein is the basis of therapeutic vaccines against HPV cancer under development (25,66).…”

Section: Discussionmentioning

confidence: 99%

Minute Time Scale Prolyl Isomerization Governs Antibody Recognition of an Intrinsically Disordered Immunodominant Epitope

Fassolari

Chemes

Gallo

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Kinetic discrimination is essential in antibody⅐antigen recognition. Results: An otherwise fast second-order reaction is limited by a slow proline isomerization of the epitope. Conclusion: The antibody recognizes the less populated isoform, suggesting presentation of the epitope as a non-native conformer. Significance: The conformational diversity of an intrinsically disordered viral epitope slows down the reaction with the antibody without specificity cost.

show abstract

“…Numerous reports describe the oncogenic potential of the E7 gene [Edmonds and Vousden, 1989;Hawley-Nelson et al, 1989], and several have described the presence of antibodies to the E7 protein in sera from patients with cervical cancer [Jochmus-Kudielka et al, 1989;Kanda et al, 1992]. Anti-E7 antibodies are found more frequently in cervical cancer patients than in matched normal controls suggesting that the generation of anti-E7 antibody may be related to the development of cervical cancer [Krchnak et al, 1990;Muller et al, 1992]. The major immunogenic region of E7 is thought to extend from the N-terminus, through the Rb binding site and casein kinase II (CKII) phosphorylation sites, to the start of the proposed zinc finger sites [Krchnak et al, 1990;Dillner, 1990;Stacey et al, 1994].…”

Section: Introductionmentioning

confidence: 99%

“…Anti-E7 antibodies are found more frequently in cervical cancer patients than in matched normal controls suggesting that the generation of anti-E7 antibody may be related to the development of cervical cancer [Krchnak et al, 1990;Muller et al, 1992]. The major immunogenic region of E7 is thought to extend from the N-terminus, through the Rb binding site and casein kinase II (CKII) phosphorylation sites, to the start of the proposed zinc finger sites [Krchnak et al, 1990;Dillner, 1990;Stacey et al, 1994]. However, the precise immunogenic regions within the CRII region of E7 have yet to be clearly defined.…”

Section: Introductionmentioning

confidence: 99%

Identification of antigenic differences between the phosphorylated and nonphosphorylated forms of the E7 protein of human papillomavirus type 16

Kee¹,

Choi²,

Song³

et al. 1998

J. Med. Virol.

View full text Add to dashboard Cite

To analyze the antigenic properties of the human papillomavirus type 16 E7 oncoprotein, two monoclonal antibodies, VD6 and IB10, that have different reactivities to the E7 protein were generated. While the VD6 antibody reacted strongly with E7 protein in CaSki cell extracts, the other antibody, IB10, showed much weaker reactivity with E7. This reactivity increased in a dosedependent manner in the presence of the casein kinase II-specific inhibitor DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole). Antigenic site estimation and an in vitro phosphorylation assay, using bacterially expressed E7 protein, demonstrated that the weak reactivity of IB10 was related to the phosphorylation status of the E7 protein. Phosphorylation of E7 reduced considerably the reactivity of IB10 but did not affect the reactivity of VD6, which reacts with the N-terminal portion of E7. In immunoprecipitation (IP) assays, IB10 precipitated weakly the E7 protein from CaSki cell extracts. Together, these data suggest that unphosphorylated E7 protein shows distinct antigenic character compared to its phosphorylated form under denaturing conditions; however, under native conditions, the phosphorylated and nonphosphorylated E7 proteins have some antigenic crossreactivity.

show abstract

Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA

Cited by 47 publications

References 13 publications

Antibody response to a synthetic peptide derived from the human papillomavirus type 6/11 L2 protein in recurrent respiratory papillomatosis: Correlation between southern blot hybridization, polymerase chain reaction, and serology

Antibody response to a synthetic peptide derived from the human papillomavirus type 6/11 L2 protein in recurrent respiratory papillomatosis: Correlation between southern blot hybridization, polymerase chain reaction, and serology

Minute Time Scale Prolyl Isomerization Governs Antibody Recognition of an Intrinsically Disordered Immunodominant Epitope

Identification of antigenic differences between the phosphorylated and nonphosphorylated forms of the E7 protein of human papillomavirus type 16

Contact Info

Product

Resources

About